Merrimack is committed to the fight against cancer. We are a science-driven community seeking to understand the complexity of the disease, engineer better solutions and deliver life-saving results for patients.
Results from three Phase 2 studies indicate that 30-50 percent of patients most at risk of progession may benefit from MM-121. MM-121 is designed to block heregulin binding to ErbB3.
Baxter gains exclusive commercialization rights for all potential indications of MM-398 outside the United States and Taiwan. Merrimack retains commercialization rights in the United States. Under the terms of the agreement,Merrimack will receive a $100 million upfront payment from Baxter and is eligible to receive up to $870 million for additional milestone and royalty payments.
Merrimack is delighted to announce its alliance with the Pancreatic Cancer Action Network, an organization dedicated to advancing research, supporting patients and creating hope for those affected by pancreatic cancer.
MM-398 in combination with 5-fluorouracil and leucovorin demonstrates a statistically significant advantage in overall survival compared to the control arm, in patients with metastatic pancreatic cancer who have been previously treated with gemcitabine.
Read more about the trial results here.
Professor Peter Sorger of Harvard Medical School discusses the science of systems biology and its potential impact on cancer care.
Merrimack was thrilled to participate in the 2nd Annual Battle of the Biotech Bands charity benefit event. The event raised over $60,000 and was attended by over 700 industry representatives. Merrimack’s BAD IDEA took top honors and awarded over $30,000 to our charity of choice - Dream Day on Cape Cod – a worthy cause serving families that have children with life-threatening illnesses or serious conditions. We thank everyone who made this event possible and look forward to participating again next year!